pancreatic cancer

cancer target detection radiopharma radio

Biotech

Revolution’s RAS inhibitor hits key goals in ph. 3 cancer trial

Daraxonrasib helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy.

James Waldron Apr 13, 2026 8:00am

pancreatic cancer pancreas model

Novocure touts positive data in metastatic pancreatic cancer

Mar 27, 2026 10:32am

Novocure TTFields

Novocure gets FDA nod for device targeting pancreatic cancer

Feb 17, 2026 4:15am

Astellas

Fierce Pharma

Astellas lifts forecast as Vyloy surge counters trial miss

Feb 5, 2026 11:00am

Racecar speeding down a track

Immuneering touts 64% survival, fueling race with Revolution

Jan 8, 2026 5:17am

Kumquats

Bayer picks Kumquat for $1.3B KRAS collaboration

Aug 12, 2025 6:29am